How semaglutides work — and what the science actually says

The biggest myth: semaglutide is just an appetite suppressant

Most people who ask how semaglutides work have already read that they "suppress appetite". That's not wrong, but it misses roughly half the story, and the half it misses is why the results from clinical trials surprised researchers as much as anyone.

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your small intestine releases after you eat. It signals to your pancreas to release insulin, tells your pancreas to hold back glucagon (which raises blood sugar), and carries messages to the hypothalamus in your brain that translate, roughly, as: you've eaten, you're satisfied, you can stop.

What semaglutide does is bind to those same receptors, but far more persistently than the hormone your gut produces naturally. Natural GLP-1 is broken down within minutes. Semaglutide is engineered to last, which is why the injection form is taken once weekly. The result isn't just that you feel less hungry at mealtimes. Many people on treatment report a quieting of what researchers sometimes call "food noise", the background mental preoccupation with eating that, for people with obesity, often runs constantly. That's a neurological effect, not a willpower correction. How semaglutides cause weight loss involves several overlapping mechanisms working together, and appetite suppression is only the most visible one.

Slowing the stomach: the part that doesn't get enough attention

The second major mechanism is gastric emptying. Semaglutide slows the rate at which food moves from your stomach into the small intestine. The practical effect: a meal that might previously have cleared your stomach in two hours takes longer, so you feel full for an extended period after eating.

This is also why the functional profile of semaglutide produces nausea in many people, especially early in treatment or after a dose increase. When the stomach is slower to empty, it can feel unsettled, particularly with large meals or high-fat food. That side effect is real and common (the NHS lists nausea, vomiting, diarrhoea and constipation among the most frequently reported effects) but for most people it's most noticeable in the first few weeks and then settles. The titration schedule, where dose increases happen gradually over months rather than weeks, is designed partly to manage this.

There are also cardiovascular signals. The SELECT trial showed that semaglutide 2.4mg reduced the risk of major cardiovascular events in adults with obesity and established heart disease, independent of weight loss. That's a separate, licensed indication, but it points to how broadly this hormone receptor class acts in the body, beyond simple appetite reduction. You can read more on the Wegovy treatment page about what the injection is licensed for in the UK.

Where the trial evidence actually comes from

The weight-loss evidence for semaglutide 2.4mg (the injectable dose licensed in the UK for weight management as Wegovy) centres on the STEP clinical programme. STEP 1, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Average weight loss on semaglutide was around 15% of body weight, compared with around 2.4% on placebo, with both groups following lifestyle guidance.

Those numbers come from a controlled trial, not from anecdote. They also come with important context: they represent averages across a population, and they assume the lifestyle component. Semaglutide is licensed alongside a reduced-calorie diet and increased physical activity, not instead of them. Clinical trials showing 15% weight loss used structured support alongside the medicine. That combination matters.

If you're curious how semaglutide's results compare with tirzepatide, a closer look at how semaglutide works versus the dual-receptor mechanism of tirzepatide can help clarify the distinction. For a broader overview of semaglutide medicines licensed in the UK, including the difference between Wegovy, Ozempic and the newer oral tablet, that page covers the landscape.

For context on how Wegovy is priced in the UK private market, that page explains what legitimate treatment costs include and why price is the wrong primary measure for a prescription medicine. The more relevant question is whether the supply chain, clinical oversight and aftercare hold up.

What this means before you start treatment

Understanding the mechanism matters for a practical reason: it helps set realistic expectations. Semaglutide is not a switch that turns off hunger permanently from day one. The first pen's job is to let your body adjust, the starting dose is lower than the maintenance dose specifically to reduce the chance of difficult side effects. The appetite and food-noise effects often become more noticeable as the dose increases over the following months.

It also matters for adherence. People who understand why meals feel different, why nausea peaks then eases, and why the titration exists are better placed to stay the course. The NHS semaglutide medicines page covers what to expect during treatment and when to contact a clinician, worth reading alongside any clinical information you receive. For more detail on how quickly the medicine begins to have an effect, how long semaglutide takes to work covers the realistic timeline week by week.

Semaglutide is a prescription-only medicine. Eligibility is assessed by a prescriber, taking into account your BMI, any existing health conditions, your medicines and your full medical history. If you'd like a clinician to review whether it might be appropriate for you, speak to our prescribers via a free consultation at our weight-loss treatments page. What arrives, if treatment is approved, is a pre-filled weekly injection pen, delivered by DPD in plain unbranded packaging, tracked to your door the next working day.